Michelle Loch, MD
Hematology & Oncology · New Orleans, LANPI 1992918171
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AstraZeneca at 43.2% of the total. 2025 is the largest year on record at $19,137, more than ten times the $436 reported in 2019. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $602.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- Gilead$14K
- Merck$8K
- Incyte Corporation$4K
- Daiichi Sankyo Inc.$2K
- Ipsen Biopharmaceuticals, Inc$160
- plus $564 from 8 others
Across 25 payments — averaging $7267.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$144K
- Veru Inc.$23K
- Merck$14K
- Seagen Inc.$250
What the payments were for
- Consulting fees$24,85150%
- Speaking & faculty fees$15,70531%
- Travel & lodging$6,45313%
- Food & beverage$2,9986%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $21,626 |
| Gilead | 16 | $13,977 |
| Merck | 6 | $7,962 |
| Incyte Corporation | 10 | $4,130 |
| Daiichi Sankyo Inc. | 7 | $1,588 |
| Ipsen Biopharmaceuticals, Inc | 2 | $160 |
| Stryker | 1 | $154 |
| Clovis Oncology, Inc. | 1 | $121 |
| Tempus AI, Inc | 1 | $120 |
| Amgen | 3 | $56 |
| Novartis | 2 | $38 |
| Bayer | 1 | $27 |
| Sanofi | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$13,698
- Enhertu$10,181
- KEYTRUDA$7,948
- Truqap$1,450
- LYNPARZA$650
- AUGMENT INJECTABLE$154
- MONJUVI$125
- SOMATULINE DEPOT$125
- Rubraca$121
How this compares
$50,006 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 20 | $313,990 |
| Anastrozole | 80 | $559 |
| Tamoxifen Citrate | 19 | $466 |
| Letrozole | 21 | $390 |
| Exemestane | 11 | $368 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
- Ralph MillettNew Orleans$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.